<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062074</url>
  </required_header>
  <id_info>
    <org_study_id>V501-059</org_study_id>
    <secondary_id>2010_005</secondary_id>
    <nct_id>NCT01062074</nct_id>
  </id_info>
  <brief_title>GARDASIL Reexamination Study (V501-059)</brief_title>
  <official_title>Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This survey is conducted for preparing application materials for re-examination under the
      Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the
      clinical usefulness of Gardasil through collecting the safety information according to the
      Re-examination Regulation for New Drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2007</start_date>
  <completion_date type="Actual">May 7, 2013</completion_date>
  <primary_completion_date type="Actual">May 7, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Any Adverse Experience</measure>
    <time_frame>Up to 14 days after any GARDASIL vaccination</time_frame>
    <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Any Adverse Drug Reaction</measure>
    <time_frame>Up to 14 days after any GARDASIL vaccination</time_frame>
    <description>An adverse drug reaction was an adverse experience for which a causal relationship to the study drug could not be ruled out</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3605</enrollment>
  <condition>Human Papillomavirus (HPV) Infection</condition>
  <arm_group>
    <arm_group_label>Korean Participants Vaccinated with GARDASIL</arm_group_label>
    <description>Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Females and males 9-26 Years Of Age who are vaccinated with GARDASIL in usual practice
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females and males 9-26 years of age who Are Vaccinated With The First Dose Of Gardasil
             For The Prevention Of Any Disease Caused By Human Papillomavirus (e.g., Cervical
             Cancer, Genital Warts, etc.) Within Local Labeling

        Exclusion Criteria:

          -  Participant Who Has A Contraindication To Gardasil According To The Local Label

          -  Participants Who Are Vaccinated With Gardasil Before Study Start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <results_first_submitted>February 7, 2014</results_first_submitted>
  <results_first_submitted_qc>February 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2014</results_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=V501-059&amp;kw=V501-059&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Korean Participants</title>
          <description>Korean participants who received vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3605"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3605"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Korean Participants</title>
          <description>Korean participants who received vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3605"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.79" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=12 years and &lt;19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3549"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Adverse Experience</title>
        <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.</description>
        <time_frame>Up to 14 days after any GARDASIL vaccination</time_frame>
        <population>Participants who received at least 1 vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Korean Participants</title>
            <description>Korean participants who received vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Experience</title>
          <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.</description>
          <population>Participants who received at least 1 vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3605"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Adverse Drug Reaction</title>
        <description>An adverse drug reaction was an adverse experience for which a causal relationship to the study drug could not be ruled out</description>
        <time_frame>Up to 14 days after any GARDASIL vaccination</time_frame>
        <population>Participants who received at least 1 vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Korean Participants</title>
            <description>Korean participants who received vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Drug Reaction</title>
          <description>An adverse drug reaction was an adverse experience for which a causal relationship to the study drug could not be ruled out</description>
          <population>Participants who received at least 1 vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3605"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after any GARDASIL vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Korean Participants</title>
          <description>Korean participants who received vaccination with GARDASIL, had Case Report Forms available, and did not violate the protocol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3605"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="330" subjects_at_risk="3605"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="504" subjects_affected="330" subjects_at_risk="3605"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>With regard to surveillance results, any publication should be agreed by the sponsor in advance</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

